New study aims to cut hormone therapy side effects in prostate cancer
NCT ID NCT07645326
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized approach to hormone therapy for men with metastatic hormone-sensitive prostate cancer. The goal is to reduce treatment intensity for lower-risk patients to minimize side effects while still controlling the cancer. About 108 participants will receive standard care adjusted to their risk level, and researchers will track how long the cancer stays controlled and how quality of life changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Georgetown University Medical Center- Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new chemo schedule tame side effects in prostate cancer?
- New drug combo aims to stall advanced prostate cancer
- Precision radiation may boost hormone therapy for advanced prostate cancer
- Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread
- New model predicts prostate cancer treatment response using PET scans
- New combo therapy tracked in german men with spread prostate cancer